Shares of Compugen Ltd. (NASDAQ:CGEN) fell 3.4% on Tuesday . The company traded as low as $6.72 and last traded at $6.84, with a volume of 139,646 shares traded. The stock had previously closed at $7.08.

A number of brokerages recently weighed in on CGEN. Zacks Investment Research upgraded shares of Compugen from a “sell” rating to a “hold” rating in a research note on Tuesday, August 2nd. FBR & Co reiterated a “buy” rating on shares of Compugen in a research note on Wednesday, June 22nd. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $10.25.

The stock’s market capitalization is $339.05 million. The company has a 50 day moving average of $6.68 and a 200-day moving average of $6.22.

Compugen (NASDAQ:CGEN) last posted its earnings results on Tuesday, August 2nd. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.04. On average, equities analysts expect that Compugen Ltd. will post ($0.56) earnings per share for the current fiscal year.

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.